Biopharmaceutical company Dizal (SSE:688192) announced on Friday that it has submitted a New Drug Application (NDA) to the US FDA for sunvozertinib, targeting locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) post-platinum-based chemotherapy.
Data from the pivotal WU-KONG1 Part B study, featured at the 2024 ASCO Annual Meeting, supports the application, highlighting significant objective response rates and a manageable safety profile.
Sunvozertinib, an oral EGFR inhibitor, previously received accelerated approval in China and Breakthrough Therapy Designations from both the US FDA and China CDE. Demonstrating efficacy across various EGFR exon20ins subtypes and brain metastasis cases, the drug addresses a key unmet need, improving outcomes for patients with poorer prognosis.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals